InsiderSignal.AI

InsiderSignal.ai

SYRE - Spyre Therapeutics, Inc.

Insider Sale by Turtle Cameron (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Turtle Cameron, serving as CEO at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $49.33 per share, for a total transaction value of $739,912.00. Following this transaction, Turtle Cameron now holds 627,540 shares of SYRE.

This sale represents a 2.00% decrease in Turtle Cameron's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Friday, April 3, 2026, 2 days after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Turtle Cameron

CEO

Cameron Turtle, DPhil, is the Chief Executive Officer and a Class I Director at Spyre Therapeutics, Inc. (SYRE), appointed in November 2023 after serving as the company's Chief Operating Officer since June 2023.[[1]](https://www.citybiz.co/article/493021/spyre-therapeutics-appoints-cameron-turtle-as-ceo/)[[2]](https://fintool.com/app/research/companies/SYRE/people/cameron-turtle) At age 35, he leads Spyre's efforts to develop next-generation therapies for inflammatory bowel disease (IBD) through antibody engineering, therapeutic combinations, and precision medicine, with lead programs targeting α4β7, TL1A, and IL-23 advancing toward clinical studies.[[1]](https://www.citybiz.co/article/493021/spyre-therapeutics-appoints-cameron-turtle-as-ceo/)[[2]](https://fintool.com/app/research/companies/SYRE/people/cameron-turtle) Dr. Turtle's career includes key roles such as Chief Strategy Officer at BridgeBio Pharma, Inc. (2021–2022), Chief Business Officer at Eidos Therapeutics, Inc. (2018–2021), Venture Partner at Foresite Labs (2022–2023), and Consultant at McKinsey & Company.[[2]](https://fintool.com/app/research/companies/SYRE/people/cameron-turtle)[[3]](https://www.biocom.org/people/cameron-turtle/) He holds a B.S. with honors in Bioengineering from the University of Washington and a D.Phil. in Cardiovascular Medicine from the University of Oxford (St. John’s College), where he was a Rhodes Scholar, Goldwater Scholar, and Forbes 30 Under 30 awardee.[[2]](https://fintool.com/app/research/companies/SYRE/people/cameron-turtle)[[3]](https://www.biocom.org/people/cameron-turtle/) He currently serves as a Director at Oruka Therapeutics.[[2]](https://fintool.com/app/research/companies/SYRE/people/cameron-turtle)

View full insider profile →

Trade Price

$49.33

Quantity

15,000

Total Value

$739,912.00

Shares Owned

627,540

Trade Date

Wednesday, April 1, 2026

3 days ago

SEC Filing Date

Friday, April 3, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Spyre Therapeutics, Inc.

Company Overview

No company information available
View news mentioning SYRE

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5340151

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime